Literature DB >> 2990946

Actions of betahistine at histamine receptors in the brain.

J M Arrang, M Garbarg, T T Quach, E Yeramian, J C Schwartz.   

Abstract

The actions of betahistine (N alpha-methyl-2-pyridylethylamine) on brain histamine receptors were investigated in a series of biological models. [3H]Mepyramine binding to H1-receptors in membranes from guinea-pig cerebellum was inhibited by betahistine with a Ki value of 31 microM. The binding of [3H]mepyramine in brain of the living mouse was inhibited by betahistine in high dosages (150-300 mg/kg). In slices from mouse cerebral cortex, betahistine induced [3H]glycogen hydrolysis in a concentration-dependent manner with an EC50 value of 9.0 microM with a maximal effect 57% that of histamine. Mepyramine and triprolidine, two H1-receptor antagonists, inhibited the betahistine-induced glycogenolysis with Ki values of 28 nM and 7 nM respectively. In slices from guinea-pig hippocampus, betahistine stimulated the accumulation of cyclic AMP in the presence of 5 microM impromidine, a H2-receptor agonist. The maximal effect represented 22% of that elicited by histamine at the H1-receptor and the EC50 value was 32.4 microM. Mepyramine at 0.1 microM partially blocked the response to betahistine. Together these various observations indicate that betahistine is a partial agonist at cerebral H1-receptors. Finally, betahistine was not an agonist at histamine H3-autoreceptors but was a rather potent antagonist of the inhibitory effect of exogenous histamine on [3H]histamine release elicited by K+ depolarisation in slices from rat cerebral cortex (Ki = 6.9 microM).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990946     DOI: 10.1016/0014-2999(85)90115-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  37 in total

Review 1.  Histamine receptors in the central nervous system.

Authors:  H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Benign paroxysmal positional vertigo: a study of two manoeuvres with and without betahistine.

Authors:  M Cavaliere; G Mottola; M Iemma
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

3.  Histamine influences body temperature by acting at H1 and H3 receptors on distinct populations of preoptic neurons.

Authors:  Ebba Gregorsson Lundius; Manuel Sanchez-Alavez; Yasmin Ghochani; Joseph Klaus; Iustin V Tabarean
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

Review 4.  Plenary lecture. A third histamine receptor subtype: characterisation, localisation and functions of the H3-receptor.

Authors:  J C Schwartz; J M Arrang; M Garbarg; H Pollard
Journal:  Agents Actions       Date:  1990-04

5.  Functional pharmacology of H1 histamine receptors expressed in mouse preoptic/anterior hypothalamic neurons.

Authors:  I V Tabarean
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

6.  Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors.

Authors:  R Burde; R Seifert; A Buschauer; G Schultz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

Review 7.  Allergy and Ménière's disease.

Authors:  M Jennifer Derebery; Karen I Berliner
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

8.  Influence of histamine receptor antagonists on the dynamics of the cutaneous hypersensitivity reaction in patients infected with schistosoma haematobium.

Authors:  J R Snyman; D K Sommers; M D Gregorowski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum.

Authors:  S J Taylor; G J Kilpatrick
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

10.  Neuropharmacology of vestibular system disorders.

Authors:  Enrique Soto; Rosario Vega
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.